Target type: biologicalprocess
The process whose specific outcome is the progression of the endocrine pancreas over time, from its formation to the mature structure. The endocrine pancreas is made up of islet cells that produce insulin, glucagon and somatostatin. [GOC:cvs]
The endocrine pancreas, responsible for hormone production and blood glucose regulation, develops through a complex and precisely orchestrated series of events. This process begins with the formation of the pancreatic bud from the endoderm of the primitive gut tube. As the bud expands and differentiates, it gives rise to both exocrine and endocrine compartments. The endocrine pancreas arises from specialized cells, known as endocrine progenitors, that arise within the developing bud. These progenitors express specific transcription factors, such as Pdx1 and Ngn3, which are critical for their commitment to endocrine fate.
Once endocrine progenitors are established, they undergo further differentiation into the various endocrine cell types, including alpha cells (glucagon), beta cells (insulin), delta cells (somatostatin), and PP cells (pancreatic polypeptide). The differentiation process is influenced by a complex interplay of signaling molecules, transcription factors, and epigenetic modifications. Notably, Notch signaling plays a crucial role in regulating the balance between endocrine and exocrine cell fates, while Wnt signaling promotes endocrine differentiation.
Endocrine cell development involves the expression of specific hormone genes and the acquisition of functional secretory granules containing the respective hormones. These granules are crucial for storing and releasing hormones in response to physiological cues.
Furthermore, the developing endocrine pancreas undergoes a process of vascularization, providing a rich blood supply for hormone release and distribution throughout the body.
The proper development of the endocrine pancreas is essential for maintaining glucose homeostasis and overall metabolic health. Dysregulation of this process can lead to various endocrine disorders, such as diabetes mellitus. Understanding the intricate molecular mechanisms governing endocrine pancreas development is crucial for developing therapeutic strategies for these disorders.'
"
Protein | Definition | Taxonomy |
---|---|---|
Eukaryotic translation initiation factor 2-alpha kinase 3 | A eukaryotic translation initiation factor 2-alpha kinase 3 that is encoded in the genome of human. [PRO:CNx, UniProtKB:Q9NZJ5] | Homo sapiens (human) |
Bcl-2 homologous antagonist/killer | A Bcl-2 homologous antagonist/killer that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q16611] | Homo sapiens (human) |
Gastric inhibitory polypeptide receptor | A gastric inhibitory polypeptide receptor that is encoded in the genome of human. [PRO:DNx, UniProtKB:P48546] | Homo sapiens (human) |
Interleukin-6 | An interleukin-6 that is encoded in the genome of human. [PRO:JAN, UniProtKB:P05231] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
raloxifene hydrochloride | raloxifene hydrochloride : A hydrochloride salt resulting from the reaction of equimolar amounts of raloxifene and hydrogen chloride. Raloxifene Hydrochloride: A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue. | hydrochloride | bone density conservation agent; estrogen antagonist; estrogen receptor modulator |
bergenin | bergenin: RN refers to (2R-(2alpha,3beta,4alpha,4aalpha,10bbeta))-isomer; structure | trihydroxybenzoic acid | metabolite |
alexidine dihydrchloride | |||
6-n-tridecylsalicylic acid | 6-n-tridecylsalicylic acid: structure given in first source | hydroxybenzoic acid | |
5,6-dehydrokawain | 5,6-dehydrokawain: from Alpinia speciosa rhizoma; RN given for cpd without isomeric designation; structure given in first source | 2-pyranones; aromatic ether | |
abt-737 | aromatic amine; aryl sulfide; biphenyls; C-nitro compound; monochlorobenzenes; N-arylpiperazine; N-sulfonylcarboxamide; secondary amino compound; tertiary amino compound | anti-allergic agent; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor | |
mk-0893 | |||
entrectinib | entrectinib : A member of the class of indazoles that is 1H-indazole substituted by [4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzoyl]amino and 3,5-difluorobenzyl groups at positions 3 and 5, respectively. It is a potent inhibitor of TRKA, TRKB, TRKC, ROS1, and ALK (IC50 values of 0.1 to 1.7 nM), and used for the treatment of NTRK, ROS1 and ALK gene fusion-positive solid tumours. entrectinib: inhibits TRK, ROS1, and ALK receptor tyrosine kinases; structure in first source | benzamides; difluorobenzene; indazoles; N-methylpiperazine; oxanes; secondary amino compound; secondary carboxamide | antibacterial agent; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor |
meiogynin a | meiogynin A: from the bark of Meiogyne cylindrocarpa; structure in first source | ||
bi 653048 bs h3po4 | BI 653048 BS H3PO4: structure in first source | ||
nms p937 | NMS P937: a polo-like kinase 1 inhibitor; structure in first source | ||
nms-p118 | NMS-P118: a PARP-1 inhibitor; structure in first source | ||
gsk2656157 | biaryl; indoles; methylpyridines; organofluorine compound; pyrrolopyrimidine; tertiary carboxamide | antineoplastic agent; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; PERK inhibitor | |
7-methyl-5-(1-((3-(trifluoromethyl)phenyl)acetyl)-2,3-dihydro-1h-indol-5-yl)-7h-pyrrolo(2,3-d)pyrimidin-4-amine | 7-methyl-5-(1-((3-(trifluoromethyl)phenyl)acetyl)-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine: inhibits protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK); structure in first source | ||
jy-1-106 | JY-1-106: a BH3 alpha-helix mimetic that functions as a pan-Bcl-2 inhibitor; structure in first source | ||
nms-e973 | NMS-E973: structure in first source |